ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
122.799,09
-1,60%
S&P 500
5.954,50
1,59%
US Dollar vs BRL
5,8854
-0,01%
Bitcoin
93.263,51
8,40%
Brent Oil
73,045
0,00%
As Melhores Corretoras Online
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Alnylam Pharmaceuticals Inc (ALNY)

  7. Alnylam Pharmaceuticals Inc (ALNY) Notícias

ALNY

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALNY
DataHoraFonteTítuloCódigoCompanhia
25/02/202509:00Business WireAlnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D DayNASDAQ:ALNYAlnylam Pharmaceuticals Inc
18/02/202518:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
18/02/202518:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
13/02/202516:14Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
13/02/202510:31Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ALNYAlnylam Pharmaceuticals Inc
13/02/202510:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALNYAlnylam Pharmaceuticals Inc
13/02/202510:00Business WireAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period ProgressNASDAQ:ALNYAlnylam Pharmaceuticals Inc
30/01/202510:00Business WireAlnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
12/01/202518:00Business WireAlnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline GoalsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
06/01/202510:00Business WireAlnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ALNYAlnylam Pharmaceuticals Inc
23/12/202410:00PR Newswire (Canada)GIVLAARI[MD] (une injection de givosiran) est maintenant remboursé au Canada pour le traitement des porphyries hépatiques aiguës (PHA) chez les adultesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
27/11/202409:00Business WireAlnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:ALNYAlnylam Pharmaceuticals Inc
25/11/202409:00Business WireAlnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with CardiomyopathyNASDAQ:ALNYAlnylam Pharmaceuticals Inc
17/11/202411:30Business WireAlnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single DoseNASDAQ:ALNYAlnylam Pharmaceuticals Inc
04/11/202410:00Business WireAlnylam to Webcast Presentations at Upcoming November Investor ConferencesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
31/10/202409:22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALNYAlnylam Pharmaceuticals Inc
31/10/202409:00Business WireAlnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period ActivityNASDAQ:ALNYAlnylam Pharmaceuticals Inc
30/10/202409:00Business WireAlnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024NASDAQ:ALNYAlnylam Pharmaceuticals Inc
18/10/202409:15PR Newswire (Canada)Alnylam Canada signe une lettre d'intention de l'Alliance pharmaceutique pancanadienne (APP) pour le remboursement public d'AMVUTTRA pour le traitement de l'amylose héréditaire à transthyrétine (ATTRh) chez les adultesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
17/10/202410:12Business WireAlnylam dépose une demande d’autorisation de mise sur le marché auprès de l’Agence européenne des médicaments pour le vutrisiran dans le cadre du traitement de l’amylose ATTR avec cardiomyopathieNASDAQ:ALNYAlnylam Pharmaceuticals Inc
17/10/202410:12Business WireAlnylam reicht bei der Europäischen Arzneimittelagentur einen Zulassungsantrag für Vutrisiran zur Behandlung von ATTR-Amyloidose mit Kardiomyopathie einNASDAQ:ALNYAlnylam Pharmaceuticals Inc
17/10/202409:00Business WireAlnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial ResultsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
16/10/202409:00Business WireAlnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with CardiomyopathyNASDAQ:ALNYAlnylam Pharmaceuticals Inc
09/10/202408:00Business WireAlnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with CardiomyopathyNASDAQ:ALNYAlnylam Pharmaceuticals Inc
03/10/202417:08Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
29/09/202410:00Business WireAlnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024NASDAQ:ALNYAlnylam Pharmaceuticals Inc
26/09/202409:00Business WireAlnylam to Webcast TTR Investor DayNASDAQ:ALNYAlnylam Pharmaceuticals Inc
30/08/202417:03Business WireAlnylam présente les résultats détaillés de l'étude de phase 3 HELIOS-B positive de Vutrisiran▼ chez les patients atteints d'amylose ATTR avec cardiomyopathie au congrès de la Société européenne de cardiologieNASDAQ:ALNYAlnylam Pharmaceuticals Inc
30/08/202414:10Business WireAlnylam präsentiert detaillierte Ergebnisse der positiven HELIOS-B-Phase-3-Studie mit Vutrisiran▼ bei Patienten mit ATTR-Amyloidose mit Kardiomyopathie auf dem Kongress der Europäischen Gesellschaft für KardiologieNASDAQ:ALNYAlnylam Pharmaceuticals Inc
30/08/202407:00Business WireAlnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology CongressNASDAQ:ALNYAlnylam Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALNY

Seu Histórico Recente

NYSE
GME
GameStop
LSE
BT.A
Bt
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios